- Home
- BBIO vs INM Comparison
BBIO vs INM Comparison
Compare BBIO & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- INM
- Stock Information
- Founded
- BBIO 2015
- INM 1981
- Country
- BBIO United States
- INM Canada
- Employees
- BBIO N/A
- INM N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- BBIO Health Care
- INM Health Care
- Exchange
- BBIO Nasdaq
- INM Nasdaq
- Market Cap
- BBIO 6.7B
- INM 3.2M
- IPO Year
- BBIO 2019
- INM N/A
- Fundamental
- Price
- BBIO $34.67
- INM $2.41
- Analyst Decision
- BBIO Strong Buy
- INM
- Analyst Count
- BBIO 12
- INM 0
- Target Price
- BBIO $57.09
- INM N/A
- AVG Volume (30 Days)
- BBIO 3.2M
- INM 46.6K
- Earning Date
- BBIO 04-29-2025
- INM 05-13-2025
- Dividend Yield
- BBIO N/A
- INM N/A
- EPS Growth
- BBIO N/A
- INM N/A
- EPS
- BBIO N/A
- INM N/A
- Revenue
- BBIO $127,415,000.00
- INM $4,832,013.00
- Revenue This Year
- BBIO $13.67
- INM N/A
- Revenue Next Year
- BBIO $118.02
- INM N/A
- P/E Ratio
- BBIO N/A
- INM N/A
- Revenue Growth
- BBIO N/A
- INM N/A
- 52 Week Low
- BBIO $21.62
- INM $1.72
- 52 Week High
- BBIO $39.47
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- BBIO 49.67
- INM 34.09
- Support Level
- BBIO $33.92
- INM $2.70
- Resistance Level
- BBIO $39.16
- INM $3.20
- Average True Range (ATR)
- BBIO 1.43
- INM 0.23
- MACD
- BBIO -0.16
- INM -0.05
- Stochastic Oscillator
- BBIO 31.05
- INM 5.26
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.